Teva announced the launch of Nuvigil (armodafinil) 200mg tablets, a new dosage strength for Nuvigil. Nuvigil is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), narcolepsy and shift work sleep disorder (SWSD), and as adjunct to standard treatment for underlying airway obstruction in OSAHS.

RELATED: Psychiatric Disorders Resource Center

The mechanism through which armodafinil promotes wakefulness is unknown. Armodafinil has wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although their pharmacologic profile is not identical to that of the sympathomimetic amines.

Nuvigil is already available in 50mg, 150mg, and 250mg strength tablets. The new 200mg tablets will be available in 30-count bottles.

For more information call (800) 896-5855 or visit